OJVM  Vol.2 No.4 , December 2012
Immunoexpression of Cathepsin D and S100A4 Protein and Their Molecular Subtyptes in Canine Mammary Carcinomas
Abstract: Cathepsin D (CD), a lysosomal protease, and S100A4 protein, a calcium binding motif, are considered to be involved in metastasis in various human cancers. No data regarding such proteins are available for canine mammary carcinomas (CMCs). Accordingly, their expression in association with known factors of prognosis was investigated in this study. For that, 66 surgically resected CMCs were submitted to an immunohistochemical evaluation using anti CD, S100A4 protein, HER2, estrogen receptor α, cytokeratin 5, and p63 antibodies, further characterizing the tumors' molecular subtype. An increase in S100A4 immunoexpression by neoplastic luminal mammary cells was associated with an infiltrative tumor mode of growth, consequently leading us to conclude that S100A4 protein could be related to progression in CMCs. Additionally, the occurrence of the luminal A molecular subtype was associated with the complex histotype in CMCs. Although we have demonstrated that changes in S100A4 protein immunoexpression occurs in CMCs, further studies are needed to determine whether this represents important independent biomarkers for CMCs.
Cite this paper: F. C. Figueiroa, B. S. Salgado, L. N. Monteiro, R. Malagoli Rocha, M. Aparecida C. Domingues, D. Martins, F. Schmitt and N. S. Rocha, "Immunoexpression of Cathepsin D and S100A4 Protein and Their Molecular Subtyptes in Canine Mammary Carcinomas," Open Journal of Veterinary Medicine, Vol. 2 No. 4, 2012, pp. 163-169. doi: 10.4236/ojvm.2012.24026.

[1]   V. R. Nerurkar, A. R. Chitale, B. V. Jalnapurkar, S. N. Naik and V. S. Lalitha, “Comparative Pathology of Canine Mammary Tumors,” Journal of Comparative Pathology, Vol. 101, No. 4, 1989, pp. 388-397. doi:10.1016/0021-9975(89)90022-4

[2]   M. C. Ramirez-Ortega, M. Frias-Mendivil, R. Delgado-Chavez, A. Menese-Garcia, J. F. Carrillo-Hernandez, M. T. Ramorez-Ugalde and I. Zeichner-Gancz, “Expresión de Catepsina D en Carcinoma Mamário y Sus Correlaciones Clinicas e Histopatológicas,” Revista de Investigación Clínica, Vol. 49, No. 5, 1997, pp. 361-368.

[3]   L. Mazzucchelli, “Protein S100A4: Too Long Overlooked by Pathologists?” American Journal of Pathology, Vol. 160, No. 1, 2002, pp. 7-13. doi:10.1016/S0002-9440(10)64342-8

[4]   E. Barthell, I. Mylonas, N. Shabani, S. Kunze, C. Kuhn, U. Jeschke and K. Friese, “Immunohistochemical Visualization of Cathepsin-D Expression in Breast Cancer,” Anticancer Research, Vol. 27, No. 4A, 2007, pp. 2035-2040.

[5]   E. Liaudet-Coopman, M. Beaujoin, D. Derocq, M. Garcia, M. Glondu-Lassis, V. Laurent-Matha, C. Prebois, H. Rochefort and F. Vignon, “Cathepsin D: Newly Discovered Functions of a Long-Standing Aspartic Protease in Cancer and Apoptosis,” Cancer Letters, Vol. 237, No. 2, 2006, pp. 167-179. doi:10.1016/j.canlet.2005.06.007

[6]   F. Capony, C. Rougeot, P. Montcourrier, V. Cavailles, G. Salazar and H. Rochefort, “Increased Secretion, Altered Processing and Glycosylation of Pro-Cathepsin D in Human Mammary Cancer Cells,” Cancer Research, Vol. 49, No. 14, 1989, pp. 3904-3909.

[7]   S. Tarabykina, T. R. Griffiths, E. Tulchinsky, J. K. Mellon, I. B. Bronstein and M. Kriajevska, “Metastasis-Associated Protein S100A4: Spotlight on Its Role in Cell Migration,” Current Cancer Drug Targets, Vol. 7, No. 3, 2007, pp. 217-228. doi:10.2174/156800907780618329

[8]   Y. G. Cho, S. W. Nam, T. Y. Kim, Y. S. Kim, C. J. Kim, J. Y. Park, J. H. Lee, H. S. Kim, J. W. Lee, C. H. Park, Y. H. Song, S. H. Lee, N. J. Yoo, J. Y. Lee and W. S. Park, “Overexpression of S100A4 Is Closely Related to the Aggressiveness of Gastric Cancer,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, Vol. 111, No. 5, 2003, pp. 539-545. doi:10.1034/j.1600-0463.2003.1110502.x

[9]   W. Misdorp, R. W. Else, E. Hellmén and T. P. Lipscomb, “Histological Classification of Mammary Tumors of the Dog and the Cat”, 2nd Edition, Armed Forces Institute of Pathology, Washington, 1999.

[10]   M. Goldschmidt, L. Pena, R. Rasotto and V. Zapulli, “Classification and Grading of Canine Mammary Tumors,” Veterinary Pathology, Vol. 48, No. 1, 2011, pp. 117-131. doi:10.1177/0300985810393258

[11]   G. D. Cassali, et al., “Consensus for the Diagnosis, Prognosis, and Treatment of Canine Mammary Tumors,” Brazilian Journal of Veterinary Pathology, Vol. 4, No. 2, 2011, pp. 153-180.

[12]   L. N. Z. Ramalho, A. Ribeiro-Silva, G. D. Cassali and S. Zucoloto, “The Expression of p63 and Cytokeratin 5 in Mixed Tumors of the Canine Mammary Gland Provides New Insights Into the Histogenesis of These Neoplasms,” Veterinary Pathology, Vol. 43, No. 4, 2006, pp. 424-429. doi:10.1354/vp.43-4-424

[13]   A. Gama, A. Alves and F. Schmitt, “Identification of Molecular Phenotypes in Canine Mammary Carcinomas with Clinical Implications: Application of the Human Classification,” Virchows Archive, Vol. 453, No. 2, 2008, pp. 123-132. doi:10.1007/s00428-008-0644-3

[14]   C. M. Perou, T. Sorlie and M. B. Eisen, “Molecular Portraits of Human Breast Tumors,” Nature, Vol. 406, No. 6796, 2000, pp. 747-752. doi:10.1038/35021093

[15]   A. F. Chambers, A. C. Groom and I. C. MacDonald, “Dissemination and Growth of Cancer Cells in Metastatic Sites,” Nature Reviews Cancer, Vol. 2, No. 8, 2002, pp. 563-572. doi:10.1038/nrc865

[16]   J. A. Henry, A. L. McCarthy, B. Angus, B. R. Westley, F. E. B. May, S. Nicholson, J. Cairns, A. L. Harris and C. H. W. Horne, “Prognostic Significance of the Estrogen Regulated Protein, Cathepsin D, in Breast Cancer,” Cancer, Vol. 65, No. 2, 1990, pp. 265-271. doi:10.1002/1097-0142(19900115)65:2<265::AID-CNCR2820650214>3.0.CO;2-1

[17]   A. K. Tandon, G. M. Clark, G. C. Chamness, J. M. Chirgwin and W. L. McGuire, “Cathepsin D and Prognosis in Breast Cancer,” New England Journal of Medicine, Vol. 322, No. 5, 1990, pp. 297-302. doi:10.1056/NEJM199002013220504

[18]   W. Domagala, G. Striker, A. Szadowska, A. Dukowicz, K. Weber and M. Osborn, “Cathepsin D in Invasive Ductal NOS Breast Carcinoma as Defined by Immunohisto-chemistry: No Correlations with Survival at 5 Years,” American Journal of Pathology, Vol. 141, No. 5, 1992, pp. 1003-1012.

[19]   J. Isola, S. Weitz, T. Visakorpi, K. Holli, R. Shea, N. Khabbaz and O. P. Kallioniemi, “Cathepsin D Expression Detected by Immunohistochemistry Has Independent Prognostic Value in Axillary Node-Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 11, No. 1, 1993, pp. 36-43.

[20]   P. Ravdin, “Evaluation of Cathepsin D as a Prognostic Factor in Breast Cancer,” Breast Cancer Research and Treatment, Vol. 24, No. 3, 1993, pp. 219-226. doi:10.1007/BF01833262

[21]   P. M. Ravdin, A. K. Tandon, C. D. C. Allred, G. M. Clark, S. A. W. Fuqua, S. H. Hilsenbeck, G. C. Chamness and C. K. Osborne, “Cathepsin D by Western Blotting and Immunohistochemistry: Failure to Confirm Correlations with Prognosis in Node Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 12, No. 3, 1994, pp. 467-474.

[22]   R. D. Cardiff, “Cathepsin D and Breast Cancer: Useful?” Human Pathology, Vol. 25, No. 9, 1994, pp. 847-848. doi:10.1016/0046-8177(94)90001-9

[23]   H. Rochefort, “The Prognostic Value of Cathepsin D in Breast Cancer. A Long Road to the Clinic,” European Journal of Cancer, Vol. 32A, No. 1, 1996, pp. 7-8. doi:10.1016/0959-8049(95)00637-0

[24]   B. R. Davies, M. P. A. Davies, F. E. M. Gibbs, R. Barraclough and P. S. Rudland, “Induction of the Metastatic Phenotype by Transfection of a Benign Rat Mammary Epithelial Cell Line with the Gene For P9ka, a Rat Calcium-Binding Protein, but Not with the Oncogene EJ-Ras-1,” Oncogene, Vol. 8, No. 4, 1993,pp. 999-1008.

[25]   M. Kriajevska, M. N. Cardenas, M. S. Grigorian, N. S. Ambartsumain, G. P. Georgiev and E. M. Lukanidin, “Non-Muscle Myosin Heavy Chain as a Possible Target for Protein Encoded By Metastasis Related Mts-1 Gene,” Journal of Biological Chemistry, Vol. 269, No. 31, 1994, pp. 19679-19682.

[26]   D. M. Helfman, E. J. Kim, E. Lukanidin and M. Grigorian, “The Metastasis Associated Protein S100A4: Role in Tumour Progression and Metastasis,” British Journal of Cancer, Vol. 92, No. 11, 2005, pp. 1955-1958. doi:10.1038/sj.bjc.6602613

[27]   S. C. Garret, K. M. Varney, D. J. Weber and A. R. Bresnick, “S100A4, a Mediator of Metastasis,” Journal of Biological Chemistry, Vol. 281, No. 2, 2006, pp. 677-680. doi:10.1074/jbc.R500017200

[28]   T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. Van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. Eystein-Lonning and A. L. Borresen-Dale, “Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications,” Proceedings of the National Academy of Sciences USA, Vol. 98, No. 19, 2001, pp. 10859-10874. doi:10.1073/pnas.191367098

[29]   T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lonning, P. O. Brown, A. L. Borresen-Dale and D. Botstein, “Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets,” Proceedings of the National Academy of Sciences USA, Vol. 100, No. 14, 2003, pp. 8418-8423. doi:10.1073/pnas.0932692100

[30]   A. Gama, A. Alves and F. Schmitt, “Expression and Significance of CK19 in Canine Malignant Mammary Tumours,” Veterinary Journal, Vol. 184, No. 1, 2010, pp. 45-51. doi:10.1016/j.tvjl.2009.02.001

[31]   B. Sousa, J. Paredes, F. Milanezi, N. Lopes, D. Martins, R. Dufloth, D. Vieira, A. Albergaria, L. Veronese, V. Carneiro, S. Carvalho, J. L. Costa, L. Zeferino and F. Schmitt, “P-Cadherin, Vimentin and CK14 for Identification of Basal-Like Phenotype in Breast Carcinomas: An Immunohistochemical Study,” Histology and Histopathology, 2010, Vol. 25, No. 8, pp. 963-974.